TY - JOUR
AU - Rebec, George V.
AB - The effects of BMY‐14802 (5,10, or 20 mg/kg), a sigma‐receptor ligand showing preclinical evidence of antipsychotic efficacy, were tested on single‐unit activity in the neostriatum of freely moving rats with or without pretreatment with 1.0 mg/kg D‐amphetamine. Relative to resting baseline, amphetamine activated the large majority of neurons that changed firing rate in close temporal association with movement. All doses of BMY‐14802 reversed this neuronal response, but the effect was most pronounced at 20 mg/kg. This dose, however, was equally likely to reverse or to induce a haloperidol‐like potentiation of those neurons inhibited by amphetamine. In contrast, 10 mg/kg BMY‐14802 consistently reversed amphetamine‐induced neuronal inhibitions. All doses of BMY‐14802 attenuated the locomotor effects of amphetamine, but only the higher doses also blocked other aspects of the amphetamine behavioral response. By itself, BMY‐14802 dose dependently inhibited motor‐related neurons, but elicited less behavioral activation than amphetamine. BMY‐14802 (20 mg/kg) also induced hindlimb ataxia and occasional backwards locomotion. Haloperidol (1.0 mg/kg) reliably suppressed both behavior and neuronal activity when injected 30 min after BMY‐14802, whether or not amphetamine pretreatment was given. Thus, BMY‐14802 shares with other neuroleptics the capacity to reverse amphetamine‐induced excitations of neostriatal motor‐related neurons, whereas other effects of BMY‐14802 reveal some haloperidol‐like actions at 20 mg/kg that do not occur at lower doses. © 1992 Wiley‐Liss, Inc.
TI - BMY‐14802, a sigma ligand and potential antipsychotic drug, reverses amphetamine‐induced changes in neostriatal single‐unit activity in freely moving rats
JO - Synapse
DO - 10.1002/syn.890120408
DA - 1992-12-01
UR - https://www.deepdyve.com/lp/wiley/bmy-14802-a-sigma-ligand-and-potential-antipsychotic-drug-reverses-ogKBXpOIb5
SP - 312
EP - 321
VL - 12
IS - 4
DP - DeepDyve
ER -